This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

LY2624803

Eli Lilly & Company

Drug Names(s): HY10275

Description: HY10275 is dual-acting histamine H1 and serotonin 5HT2a modulator.

Deal Structure: HY10275 was originally developed by Hypnion using their SCORE bioassay technology, originally licensed from Stanford University.

In March 2007, Eli Lilly and Hypnion announced that the companies have signed a definitive merger agreement whereby Lilly will acquireHypnion. Financial terms of the deal were not disclosed. The acquisition was closed in April 2007.


LY2624803 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug